SI-B037
/ Systimmune, Sichuan Biokin Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 25, 2026
Redmond, Washington-based SystImmune, the US subsidiary of Chengdu-based Sichuan Biokin Pharmaceutical, received US FDA clearance of an investigational new drug application for SI-B037, an investigational bispecific antibody for advanced solid tumors.
(AllSci Corp)
- "SystImmune has not disclosed the molecular targets of SI-B037, describing the antibody only as targeting immunosuppression and other synergistic mechanisms. The planned Phase I/Ib study will evaluate dosing and characterize initial clinical activity in advanced solid tumors."
IND • Solid Tumor
1 to 1
Of
1
Go to page
1